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Introduction
In 1854, the term “amyloid”, meaning starch or cellu-
lose, was first used in the description of a liver speci-
men at autopsy by Virchow.1 Amyloid deposits can be
identified on the basis of their apple-green birefrin-
gence under a polarized light microscope after stain-
ing with Congo red, as well as the presence of rigid,
nonbranching fibrils, 7.5–10 nm in diameter, on elec-
tron microscopy.2 The kidneys and heart are the most
commonly involved organs in amyloidosis.3 Liver and
gastrointestinal tract involvement is less common, and
the symptoms are usually mild.3,4 In this article, we
present a case of systemic amyloidosis presenting as a
rare cause of hepatic failure.
Case Report
A 57-year-old male patient presented at another hospi-
tal with a history of duodenal ulcer involving bleeding
and oral hemorrhagic bullae in April 2008. Thrombo-
cytopenia and hyperbilirubinemia were diagnosed and
persisted for 2 months. He was then admitted to our
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hospital for persistent thrombocytopenia and jaundice
in June 2008. Physical examination revealed icteric
sclera and hepatosplenomegaly. No hepatic enceph-
alopathy was found. Blood counts were as follows:
white blood cell count, 11,600/mm3 (normal, 4,800–
10,800/mm3); hemoglobin, 11.6 g/dL (normal, 12–
16 g/dL); and platelet count, 97,000/mm3 (normal,
130,000–400,000/mm3). Serum biochemistry test re-
sults were: alanine aminotransferase, 23IU/L (normal,
0–40IU/L); alkaline phosphatase, 310U/L (normal,
10–100 U/L); γ-glutamyltransferase, 139 U/L (nor-
mal, 8–61U/L); albumin, 3.1g/dL (normal, 3.7–5.3g/
dL); total bilirubin, 3.2mg/dL (normal, 0.2–1.6g/dL);
and direct bilirubin, 2.0 (normal, 0–0.3mg/dL). Urine
routine results were: protein trace; 0–2 red blood
cells/high-powered field; and 0–2 white blood cells/
high-powered field. Disseminated intravascular coag-
ulation profile was positive (Table 1). Autoimmune
profiles, including antinuclear antibody, antimito-
chondrial antibody, antismooth muscle antibody and
rheumatoid factor, were negative. Hepatitis B and C
markers were both negative.
Abdominal sonography showed a moderate amount
of ascites and multifocal hypoechoic regions in the
enlarged spleen (Figure 1). Heterogeneous enhance-
ment of the liver with focal low attenuation regions
and splenomegaly with poor contrast enhancement
(Figure 2) were shown on abdominal computed to-
mography (CT). Magnetic resonance imaging (MRI)
revealed relatively high signal intensity on T1-weighted
imaging (T1WI), with heterogeneous enhancement
of the liver parenchyma and high signal intensity on
T1WI, low signal intensity on T2-weighted imaging
(T2WI), and poor contrast enhancement of the spleen
(Figure 3).
As no definite diagnosis was made, diagnostic
laparoscopy with liver biopsy was subsequently per-
formed. The gross appearance of the liver was normal.
Microscopically, diffuse amyloid deposition was noted
in the sinusoidal spaces (Figure 4A). Typical apple-
green birefringence was demonstrated on polarized
light microscopy by Congo red staining (Figure 4B).
Kappa and Lambda stains were both positive. Portal
areas were free of amyloid deposition. There was nei-
ther cirrhosis nor malignancy in the liver specimen. In
addition, serum electrophoresis and immunoelec-
trophoresis showed a moderate increase of γ-globulin
and mild increase of β-globulin and α2 without mon-
oclonal spike. Colonoscopic biopsy from the rectum
also disclosed amyloidosis. Hence, systemic amyloi-
dosis was diagnosed and colchicine prescribed. How-
ever, liver function deteriorated and intermittent
gastrointestinal bleeding was found during the patient’s
course of hospitalization. The patient died due to uncor-
rectable coagulopathy and massive gastrointestinal
bleeding in August 2008. The final diagnosis was idio-
pathic amyloidosis with hepatic failure.
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Table 1. Autoimmune profiles and viral hepatitis markers
DIC profile Data Normal range
D-dimer (μg/mL) 12.13 < 2.09
FDP (μg/mL) 27.9 < 5.0
INR 1.78 0.85–1.15
APTT (s) 55 23.9–35.5
Fibrinogen (mg/dL) 194
DIC = disseminated intravascular coagulation; FDP = fibrinogen degradation
products; INR = international normalized ratio; APTT = activated partial
thromboplastin time.
Figure 1. Abdominal sonography shows splenomegaly with multi-
focal hypoechoic regions.
Figure 2. Abdominal computed tomography reveals heteroge-
neous enhancement with focal low attenuation regions in the liver
parenchyma and splenomegaly with poor contrast enhancement.
SP = spleen.
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Figure 3. On abdominal magnetic resonance imaging, the liver parenchyma has: (A) relatively high signal intensity on T1-weighted imag-
ing; and (B) low signal intensity on T2-weighted imaging; with (C) heterogeneous enhancement in the arterial phase. Heterogeneous sig-
nals of splenic parenchyma with: (A) high signal on T1-weighted imaging; (B) low signal on T2-weighted imaging; and (C, D) poor contrast
enhancement were noted.
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Figure 4. (A) Liver biopsy specimen stained with hematoxylin-eosin-safran shows diffuse amorphous substance deposited in the sinu-
soidal spaces (800×). (B) Typical apple-green birefringence of amyloid deposition is demonstrated on polarized light microscopy by
Congo red staining.
Discussion
Amyloidosis is a disorder of extracellular deposition of
insoluble proteinaceous material.3 There are 2 major
classification systems applied for amyloidosis. The first
classifies the disease according to the structure of the
amyloid fibrils. Among the numerous types of amyloid
fibril, amyloid A protein (AA type), amyloid light chain
(AL type), and β2-microglobulin (β2-MG type) are the
most prevalent.5 AA type is usually found in chronic
inflammatory disease such as tuberculosis, neoplasia,
rheumatoid arthritis, osteomyelitis, primary biliary
cirrhosis, and Crohn’s disease.5 AL type is associated
with the generalized deposition of excess light chains,
and 15% of patients with this type will also have multiple
myeloma.4 The β2-MG type is related to long-term
hemodialysis.5
Another widely applied system classifies amyloidosis
into systemic type and localized type based on the
clinical manifestations and the organ involved.6 In the
localized type, amyloid infiltration is restricted to an
isolated organ, while the deposits can be found in mul-
tiple organ systems in the systemic type. In a previous
study, only a quarter of patients had involvement of a
single organ at presentation; the remaining patients had
involvement of 2 organs (36%) or ≥ 3 organs (39%).3
Systemic amyloidosis was found in 0.7% of 11,912
autopsies between 1932 and 1960.7 It usually presents
after the 5th decade of life and is male-predominant.6
The most common symptoms are fatigue, weight loss,
edema and proteinuria renal dysfunction. The most
commonly involved organs are the kidneys (46%) and
the heart (30%).3 The liver (9%) and gastrointestinal
tract (7%) are less commonly involved, but the inci-
dence is increased when systemic amyloidosis is con-
firmed.3,4 Hepatic involvement was found in 56–95%
of patients with systemic amyloidosis.7,8 It was present in
60% of cases with AA amyloidosis, 62–90% with AL
amyloidosis, and 22–43% with multiple myeloma-
associated amyloidosis.7,9
The diagnosis of amyloidosis demands careful
clinical evaluation and is established by tissue biopsy.
Notably, the prognosis is worse for patients with the
systemic type compared to those with the localized
type.9 Accordingly, it is crucial to differentiate between
them by laboratory, radiological and even pathologi-
cal examinations. The common organs to be biopsied
in the clinical setting are the rectum, subcutaneous
fat, kidney, bone marrow, small intestine and liver.4 In
our patient, systemic amyloidosis was diagnosed by tis-
sue biopsy from both the liver and rectum. Although
liver involvement is common and hepatomegaly is
noted in 40–50% of patients with systemic amyloido-
sis, jaundice, elevated serum aminotransferase con-
centrations, and impaired liver functional reserve are
relatively rare.4,7,10 A previous study demonstrated that
severe cholestatic presentations appear to be largely
limited to patients with advanced systemic AL amy-
loidosis.11 Coagulation problems in amyloidosis are
historically associated with bleeding tendencies.12 In-
creased clotting has been observed in isolated cases
diagnosed with low-grade disseminated intravascular
coagulation.12
Our 57-year-old male patient presented with hepatic
decompensation as the initial symptom of systemic amy-
loidosis, with rapid deteriorating clinical manifesta-
tions. Consequently, clinicians should maintain a high
index of suspicion so that they can promptly diagnose
systemic amyloidosis with liver involvement and closely
monitor clinical outcomes. The outcome for patients
may be lethal if there is misdiagnosis, delayed diagnosis
or if they are not prescribed appropriate management.
Our patient also manifested with splenic involve-
ment. In a previous study, splenomegaly was often asso-
ciated with hepatomegaly and was found in 15–31% of
patients with systemic amyloidosis.4 In addition, splenic
dysfunction or hyposplenism, which is from amyloid
infiltration, occurs in 24% of cases.10 This has been re-
ported to cause spontaneous splenic rupture and might
increase the risk of serious infection.4
Radiologic findings of hepatic involvement are
usually nonspecific.5 Abdominal sonography may show
heterogeneous echogenicity of liver parenchyma. CT
findings include diffuse or focally decreased parenchyma
attenuation and triangular-shaped hepatomegaly. MRI
shows significantly increased signal intensity on T1WI
without a significantly altered signal intensity on
T2WI.5 Regarding splenic amyloidosis, heterogeneous
echogenecity of splenic parenchyma, splenomegaly with
low signal intensity on T2WI, and poor contrast en-
hancement on MRI are the usual imaging findings. Ret-
rospectively, in our patient, the hypoechoic areas of the
spleen on ultrasonography and decreased parenchymal
attenuation of the liver and spleen on CT and MRI
hinted at liver amyloidosis and splenic involvement.
The treatment of amyloidosis is directed both
toward the affected organs and to the specific type of
the disease.1 In AA-type amyloidosis, the treatment mo-
dalities are based on the underlying diseases and aim
to reduce the amyloid precursor by intensive anti-
inflammatory/immunosuppressive therapy.11 If the
etiology cannot be identified in AA-type amyloidosis,
empirical anti-inflammatory treatment may be pre-
scribed.13 In AL-type amyloidosis, oral mephalan and
prednisolone have confirmed efficacy over no therapy
or therapy with colchicine only.1 Treatment with high-
dose intravenous melphalan with autologous blood
stem-cell support results in complete remission of the
plasma-cell dyscrasia and normalization of the num-
ber of plasma cells in bone marrow in 65% of patients.1
In < 10% of patients with AL amyloidosis, progressive
heart failure results in mortality. Cardiac transplanta-
tion, followed by intensive chemotherapy, may be an
alternative treatment for these patients.1 The prognosis
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of amyloidosis is diverse, but is generally poor if the
disease is untreated.1 Factors associated with a poor
prognosis include older age, reduced serum albumin
concentration, end-stage renal failure at baseline, and
the degree by which serum amyloid A protein concen-
tration is elevated during follow-up.13
In conclusion, although amyloidosis rarely presents
with hepatic failure, it should be considered in patients
with signs of liver decompensation. Clinicians should
be aware of this rare but potentially lethal presentation
and arrange appropriate treatment promptly.
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